Table 1 |
|||||||||||
| Clinical and histologic features of 16 patients with ENKTL | |||||||||||
| Patient no. | Age | Sex | Primary sites | Ann Arbor stage | LDH level | B symptoms | IPI | Therapy | Response to treatment | LMP1 expression (IHS) | LMP2A expression (IHS) |
| 1 | 36 | M | Nasal cavity | II | Normal | Positive | LI | CHOP + FLAG | PR | 6 | 6 |
| 2 | 36 | M | Oropharynx | III | High | Positive | HI | CHOP | PR | 4 | 2 |
| 3 | 57 | M | Nasal cavity | II | Normal | Negative | HI | Surgery + CHOP | CR | 2 | 1 |
| 4 | 55 | M | Larynx | I | Normal | Positive | LI | Surgery + CHOP | PR | 8 | 1 |
| 5 | 49 | F | Nasal cavity | II | High | Negative | L | Surgery | NR | 1 | 4 |
| 6 | 51 | M | Nasal cavity | I | High | Negative | LI | CHOP + Radiotherapy | PR | 2 | 1 |
| 7 | 67 | M | Nasal cavity | II | Normal | Positive | HI | CHOP + GDP + CVAD | CR | 9 | 4 |
| 8 | 25 | M | Oropharynx, palate | II | Normal | Negative | L | CHOPE + ICE + Radiotherapy | CR | 1 | 9 |
| 9 | 71 | M | Nasal cavity | I | High | Positive | LI | CHOP + SMILE | CR | 4 | 2 |
| 10 | 36 | M | Nasal cavity | II | Normal | Negative | L | CHOP | PR | 6 | 1 |
| 11 | 63 | M | Nasal cavity | I | Normal | Negative | L | CEVP + Radiotherapy | PR | 2 | 1 |
| 12 | 56 | M | Nasal cavity | II | Normal | Positive | LI | Surgery + CHOP | PR | 3 | 2 |
| 13 | 66 | F | Larynx | II | High | Positive | HI | Surgery | CR | 6 | 8 |
| 14 | 47 | M | Nasopharynx | I | Normal | Negative | L | VEPA + Radiotherapy | CR | 8 | 1 |
| 15 | 51 | F | Nasal cavity | III | Normal | Positive | HI | DICE + SMILE | PR | 9 | 9 |
| 16 | 27 | M | Nasal cavity | II | Normal | Negative | LI | Surgery + CHOP | CR | 3 | 6 |
LDH: lactate dehydrogenase; IPI: international prognostic index; IHS: immunohistochemistry score; LMP1: latent membrane protein 1; LMP2A: latent membrane protein 2A; L: low risk; LI: low-intermiediate risk; HI: high-intermiediate risk; CR: complete remission; PR: partial remission; NR: no response; CHOP: cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; FLAG: fludarabine, arabinosylcytosine, granulocyte colony-stimulating factor; GDP: gemcitabine, dexamethasone, cisplatin; CVAD: cyclophosphamide, vindesine sulfate, adriamycin, cisplatin; CHOPE: cyclophosphamide, hydroxydaunomycin, oncovin, prednisone, etoposide; ICE: ifosfamide, cisplatin, etoposide; SMILE: steroid, methotrexate, ifosfamide, l-asparaginase, etoposide; CEVP: cyclophosphamide, epirubicin, vincristine, prednisone; VEPA: vincristine, cyclophosphamide, doxorubicin, predonisolone; DICE: dexamethasone, ifosfamide, cisplatin, etoposide.
Mao et al. Diagnostic Pathology 2012 7:178 doi:10.1186/1746-1596-7-178